NCT02003313CompletedPhase 3
Immunogenicity and Safety of Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine in More Than 2 Years Old Children and Adults
Beijing Minhai Biotechnology Co., Ltd1 site in 1 country1,260 target enrollmentStarted: November 1, 2013Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Enrollment
- 1,260
- Locations
- 1
- Primary Endpoint
- Percentage of subjects exhibiting a >=4 fold increase in rSBA titers level from pre-vaccination to post-vaccination
Study Overview
Brief Summary
The purpose of this double-blind study is to evaluate the safety, reactogenicity and immunogenicity of Group A,C,Y and W135 Meningococcal Polysaccharide Vaccine in 2 to 30 years-old Children and Adults. All subjects will receive 1 dose of Group A,C,Y and W135 Meningococcal Polysaccharide Vaccine.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Triple (Participant, Care Provider, Investigator)
Eligibility Criteria
- Ages
- 2 Years to 30 Years (Child, Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Subjects who the investigator believes will comply with the requirements of the protocol should be enrolled in the study.
- •Healthy permanent residence 2-30 years old.
- •Subjects and parent/guardian able to attend all scheduled visits and comply with all study procedures.
- •Axillary temperature ≤37.0 ℃.
Exclusion Criteria
- •History of meningitis infection or vaccination of meningococcal vaccine within the past 6 months.
- •Allergic history or any SAE after vaccination, such as allergy, urticaria, dyspnea, angioedema, celialgia.
- •Patients administered with immunosuppressive agents, cytotoxicity factor or corticosteroids in the 6 months preceding the vaccine trial.
- •Receipt of blood or blood-derived products in the 3 months preceding vaccination.
- •Participation in another clinical study investigating a vaccine, drug in the 30 days preceding vaccination.
- •Receipt of any live virus vaccine in the 15 days preceding vaccination.
- •Receipt of any subunit vaccine and inactivated vaccine in the 7 days before vaccination.
- •Febrile illness (temperature ≥ 38°C) in the 3 days or any acute illness/infection in the 7 days preceding vaccination.
- •Thrombocytopenia.
- •History of thyroid gland excision or treatment for thyroid gland disease in last 12 months.
- •Functional or anatomic asplenia.
- •History of eclampsia, epilepsy, encephalopathy and mental disease or family disease.
- •Chronic disease (such as Down syndrome, diabetes, sickle cell anemia or neurologic disease, Guillain-Barre Syndrome).
- •Known or suspected diseases, including: respiratory system disease, acute infection or active stage of chronic disease, HIV infection of children or mothers, cardiovascular disease, acute hypertension, cancer treatment, skin disease, etc.
- •In pregnancy or lactation or pregnant women during the test plan
- •Any condition that, in the judgment of investigator, may affect trial assessment.
Arms & Interventions
Group T
Experimental
Participants of enrollment will receive 1 dose on Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine.
Intervention: Group T (Biological)
Group C
Active Comparator
Participants of enrollment will receive 1 dose on Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine.
Intervention: Group C (Biological)
Outcomes
Primary Outcomes
Percentage of subjects exhibiting a >=4 fold increase in rSBA titers level from pre-vaccination to post-vaccination
Time Frame: 28 days after vaccination
Secondary Outcomes
- to evaluate the adverse reactions after vaccination(within 28 days after vaccination)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Comparison of the Safety and Immune Response of Three Different Lots of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2004/2005InfluenzaNCT00161811Alachua Government Services, Inc.1,400
Completed
Phase 1
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Staphylococcal Investigational Vaccine in Healthy AdultsInfections, StaphylococcalNCT01160172GlaxoSmithKline88
Completed
Phase 2
Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy WomenRespiratory Syncytial Virus InfectionsNCT02360475GlaxoSmithKline507
Completed
Phase 2
Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy AdultsInfluenzaNCT00328107Protein Sciences Corporation459
Recruiting
Phase 1
A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney TransplantHerpes ZosterNCT04006808GlaxoSmithKline184